5 completed, 1 recruiting, 1 terminated, 1 unknown. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow Auranofin: new trials by email Literature Review of Auranofin trials Research Report on Auranofin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals Maraviroc, Dolutegravir, Dendritic Cell Vaccine - Hiv, HIV I Infection | Phase 2 | Recruiting | Federal University of São Paulo | 70 | 2026-07-15 | 2026-08-19 |
| Auranofin and Sirolimus in Treating Participants With Ovarian Cancer Auranofin, Laboratory Biomarker Analysis, Sirolimus - Ovarian Serous Tumor, Recurrent Ovarian Carcinoma | Phase 2 | Terminated | Mayo Clinic | 22 | 2018-03-30 | 2025-05-08 |
| Auranofin for Giardia Protozoa Auranofin, Placebo - Amoebic Dysentery, Giardiasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 93 | 2016-11-06 | 2023-01-26 |
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Temozolomide, Aprepitant, Minocycline - Glioblastoma | Phase 1 / Phase 2 | Completed | University of Ulm | 10 | 2016-11-01 | 2021-10-05 |
| TB Host Directed Therapy Everolimus 0.5 MG, Auranofin 6 MG, Vitamin D3 - Tuberculosis | Phase 2 | Unknown | The Aurum Institute NPC | 200 | 2016-11-01 | 2019-01-10 |
| Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Auranofin, Sirolimus, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 29 | 2014-05-14 | 2025-09-05 |
| Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome auranofin, placebo, questionnaire administration - Pain | Phase 2 | Completed | Mayo Clinic | 30 | 2014-02-19 | 2019-04-23 |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) auranofin - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma | Phase 2 | Completed | University of Kansas Medical Center | 15 | 2011-09-01 | 2016-01-18 |
| Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection Auranofin - HIV | Phase 1 / Phase 2 | Withdrawn | Vaccine and Gene Therapy Institute, Florida | 2015-02-26 |
Acquired Immunodeficiency Syndrome (1) · Adenocarcinoma of Lung (1) · Amebiasis (1) · Carcinoma, Non-Small-Cell Lung (1) · Dysentery, Amebic (1) · Giardiasis (1) · Glioblastoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic (1) · Ovarian Neoplasms (1) · Pain (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Tuberculosis (1)
Mayo Clinic (3) · Federal University of São Paulo (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · The Aurum Institute NPC (1) · University of Kansas Medical Center (1) · University of Ulm (1) · Vaccine and Gene Therapy Institute, Florida (1)
United States (5) · Bangladesh (1) · Brazil (1) · Germany (1) · South Africa (1)
Aminah Jatoi (1) · Aminah Jatoi, M.D. (1) · Marc-Eric Halatsch, MD (1) · Patrick D Yeramian, MD (1) · Robert S Wallis, MD,FIDSA (1) · Suman Kambhampati, MD (1) · Yanyan Lou, M.D., Ph.D. (1)
PMID 35254001, PMID 41114938, PMID 33740465, PMID 34620071, PMID 34959641, PMID 38396172
P30CA015083 (1), R21CA153000 (1)